PHLPP1在卵巢浆液性囊腺癌的表达及对预后的影响  

The Influence of the Expression of PHLPP1 to the Prognosis of Ovarian Serous Cystadenocarcinoma

作　　者：刘凤华[1] 肖会廷[1] 田菁[1] 吴江华[1] 郝权[1] 

机构地区：[1]天津医科大学肿瘤医院妇科肿瘤科天津市肿瘤防治重点实验室国家肿瘤临床研究中心,天津300060

出　　处：《实用妇产科杂志》2016年第2期146-150,共5页Journal of Practical Obstetrics and Gynecology

基　　金：天津市卫生局科技基金(编号:2013KZ089);天津医科大学肿瘤医院院级课题(编号:B1212)

摘　　要：目的：检测PHLPP1蛋白在卵巢浆液性囊腺癌中的表达,探讨PHLPP1的表达对初治卵巢浆液性囊腺癌耐药及预后的影响。方法：收集整理2007年1月至2009年8月资料完整且病理确诊的卵巢浆液性囊腺瘤26例和卵巢浆液性囊腺癌93例的临床资料,对所有患者术后石蜡组织行免疫组织化学检测PHLPP1与磷酸化丝/苏氨酸蛋白激酶B（p-AKT）的表达。通过Kaplan-Meier法进行生存分析,并对p-AKT与PHLPP1的表达相关性进行分析,COX回归模型对影响卵巢浆液性囊腺癌预后的临床及病理因素进行分析。结果：PHLPP1在卵巢浆液性囊腺瘤的高表达率为61.5%,在浆液性囊腺癌高表达率为41.9%,两组比较差异有统计学意义（χ~2=42.10,P〈0.001）。PHLPP1与p-AKT表达呈负相关（r=-0.513,P〈0.001）。PHLPP1表达与卵巢浆液性囊腺癌恶性程度、淋巴结转移、远处转移、铂类耐药及分期相关,PHLPP1无或低表达及p-AKT高表达、淋巴结转移、远处转移是影响其预后的独立危险因素。卵巢浆液性囊腺癌PHLPP1高表达组中位生存期（MST）为48.0±7.6月,平均复发时间为10.2±3.3月;无或低表达组MST 34.0±4.0月,平均复发时间6.0±2.9月,高表达组均高于无或低表达组（P〈0.05）。PHLPP1高表达组5年生存率为25.0%,无或低表达组5年生存率为16.1%。p-AKT高表达组5年生存率为9.4%,而无或低表达组为23.3%。结论：PHLPP1在卵巢浆液性囊腺瘤中的高表达率显著高于浆液性囊腺癌,PHLPP1表达与卵巢浆液性囊腺癌患者耐药及预后密切相关。PHLPP1高表达者预后明显好于无或低表达者,PHLPP1缺乏是浆液性囊腺癌的独立危险因素。Objective： To study the expressions of PHLPP1 and the effect of its expression on the drug resist-ance and prognosis of ovarian serous cystadenocarcinoma. M ethods： Collect the medical records of patients with ovarian serous cystadenoma（ 26 cases） and ovarian serous cystadenocarcinoma（ 93 cases） treated in our hospital from 2007 to 2009 confirmed by pathological diagnosis. All of the postoperative paraffin organizations were collected to do the immunohistochemical detection of the expression of PHLPP1,phosphorylated AKT. Survival time was analyzed by Kaplan-Meier method,chi-square test to analysis the relation of the expression of AKT and PHLPP1. COX regression analysis was used to analyze the prognosis factors of ovarian serous cystadenocarcinoma. Results： The expression rate of PHLPP1 was 61. 5% in ovarian serous cystadenoma; the expression rate was 41. 9% in ovarian serous cystadenocarcinoma. There was statistically difference between the two groups（ χ2= 42. 10,P〈0. 001）. There was negative correlations between the expressions of PHLPP1 and AKT（ r =-0. 513,P〈0. 001）. The expression of PHLPP1 was related with prognosis,lymph node metastasis,long distance metastasis,drug resistance,clinical stage,and low or no expression of PHLPP1 and high expression of p-AKT,lymph node metastasis,long distance metastasis were the independent risk factors of the prognosis. The median survival time（ MST） in PHLPP1 high expression group was 48. 0 ± 7. 6 months,the average recurrence time was10. 2 ± 3. 3 months. MST with low expression group was 34. 0 ± 4. 0 months and the average recurrence time was 6. 0 ± 2. 9 months,the difference was significant（ P〈0. 05）. The 5 years survival rate in PHLPP1 high expression group and low or no expression group was 25. 0% and 16. 1% respectively,the 5 years survival rate in p-AKT high expression group and low or no expression group was 9. 4% and 23. 3% respectively. Conclusions：The high expression rate of PHLPP1 in ovarian serous cystadenoma is signific

关 键 词：浆液性囊腺癌 浆液性囊腺瘤 PHLPP蛋白 磷酸化丝/苏氨酸蛋白激酶B 

分 类 号：R737.31[医药卫生—肿瘤]